(1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives
申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP0371564A2
公开(公告)日:1990-06-06
Novel (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives of formula
the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein -X1 =X2- is -CH = CH-, -CH = N-, or -N = CH-; R is hydrogen or C1-6alkyl; Y is hydrogen, C1-10alkyl, C3-7cycloalkyl, Arl, Ar2-C1-6alkyl, C2-6alkenyl or C2-6alkynyl; Z is a radical of formula
which compounds are useful for treating disorders which are characterized by an excessive proliferation and/or abnormal differentiation of epithelial tissues: pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.
Application of Organolithium in Organic Synthesis: A Simple and Convenient Procedure for the Synthesis of More Complex 6-Substituted 3 H -Quinazolin-4-ones
作者:Gamal A. El-Hiti
DOI:10.1007/s00706-003-0110-5
日期:2004.3.1
6-Methyl-3 H -quinazolin-4-one reacted with alkyllithium reagents at −78°C in THF to give 2-alkyl-1,2-dihydro-6-methyl-3 H -quinazolin-4-ones in high yields. However, no reaction took place when LDA was used as the lithium reagent. 6-Bromo-3 H -quinazolin-4-one reacted with excessive butyllithium to give 2-butyl-1,2-dihydro-3 H -quinazolin-4-ones in very good yields. However, the lithiation of 6-bromo-3
(1H-azol-1-ylmethyl)substituted quinazoline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increased proliferation and/or abnormal differentiation of epithelial tissues.